FDA
-
-
-
-
-
-
-
Synergy Pharma (SGYP) Names Dr. Melvin K. Spigelman as Chairman
-
-
-
-
-
-
-
Synergy Pharmaceuticals Presents New Analyses Supporting the Use of TRULANCE® (plecanatide) in Two Patient Populations at the American College of Gastroenterology (ACG) Annual Scientific Meeting
-
-
-
-
-
-
-
Synergy Pharmaceuticals Announces TRULANCE® (plecanatide) Added to Express Scripts 2019 National Preferred Formulary List
-
-
-
-
-
-
-
Synergy Pharmaceuticals Highlights New Data at Digestive Disease Week (DDW) 2018 Linking Uroguanylin Deficiency to Chronic Idiopathic Constipation (CIC) and Irritable Bowel Syndrome with Constipation
-
-
-
-
-
-
-
Cipher Pharmaceuticals Acquires Exclusive Canadian Rights to FDA-Approved TRULANCE® from Synergy Pharmaceuticals
-
-
-
-
-
-
-
Synergy Pharma (SGYP) TRULANCE Approvd by FDA for IBS-C in Adults
-
-
-
-
-
-
-
Synergy Pharmaceuticals Reports Third Quarter 2017 Financial Results and Business Update
-
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

